Table of Content

08 March 2024, Volume 51 Issue 3 Previous Issue    Next Issue

For Selected:

Download Citations EndNote Reference Manager ProCite BibTeX RefWorks

Toggle Thumbnails

Original Articles

Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity， proliferation， and apoptosis of multiple myeloma cells Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan 2024, 51 (3):  129-136.  doi: 10.3760/cma.j.cn371439-20231130-00021 Abstract ( 81 )   HTML ( 21 )   PDF (3641KB) ( 56 )   Save Objective To study the effects and potential mechanisms of the combination of dihydroartemisinin and carfilzomib on the activity， proliferation， and apoptosis of multiple myeloma ARD cell lines. Methods In vitro cultivation of multiple myeloma ARD cells involved treating the cells with dihydroartemisinin at concentrations of 0， 5， 10， 20， 40， and 80 μg/ml， and with carfilzomib at concentrations of 0， 5， 10， 20， 40， and 80 nmol/L. The ARD cells were divided into a control group （no treatment）， a dihydroartemisinin group （2 μg/ml）， a carfizomib group （8 nmol/L）， and a combination group （dihydroartemisinin 2 μg/ml + carfizomib 8 nmol/L）. Cell activity and proliferation were assessed by MTT assay and EdU-488 assay； cell apoptosis was evaluated using live cell/dead cell dual staining and flow cytometry. The expression levels of apoptosis-related proteins were examined using Western blotting analysis. Results The cell survival rates of ARD cells treated with 0， 5， 10， 20， 40， and 80 μg/ml dihydroartemisinin were （100.00±2.18）%， （50.22±3.09）%， （37.39±2.34）%， （30.42±1.79）%， （23.80±1.12）%， and （18.04±0.79）%， respectively， and there was a statistically significant difference （F=653.30， P<0.001）. With the increase of drug concentration， ARD cell activity decreased gradually （all P<0.05）. The cell survival rates of ARD cells treated with 0， 5， 10， 20， 40， and 80 nmol/L carfilzomib were （100.00±1.12）%， （83.98±2.95）%， （67.27±2.10）%， （58.24±2.02）%， （46.34±1.14）%， and （37.47±1.36）%， respectively， and there was a statistically significant difference （F=227.40， P<0.001）. With the increase of drug concentration， ARD cell activity decreased gradually （all P<0.05）. The cell survival rates for the control group， dihydroartemisinin group， carfilzomib group， and combination group were （100.00±2.67）%， （67.23±0.57）%， （76.23±2.83）%， and （27.06±1.09）%， respectively， and there was a statistically significant difference （F=655.60， P<0.001）. There were statistically significant differences in the dihydroartemisinin group， carfilzomib group， and combination group compared with control group （all P<0.001）. There were statistically significant differences in the dihydroartemisinin group and carfilzomib group compared with combined group （both P<0.001）. The EdU-488 experiment showed that the EdU-positive rates of ARD cells in the control group， dihydroartemisinin group， carfilzomib group， and combination group were （100.00±8.17）%， （68.07±6.14）%， （85.04±2.78）%， and （19.62±3.83）%， respectively， and there was a statistically significant difference （F=115.20， P<0.001）. There were statistically significant differences in the dihydroartemisinin group， carfilzomib group， and combination group compared with control group （P<0.001； P=0.047； P<0.001）. There were statistically significant differences in the dihydroartemisinin group and carfilzomib group compared with combined group （both P<0.001）. The live cell/dead cell dual staining experiment showed， under bright-field observation， the cell morphology was intact in the control group. In all the drug groups， the cell morphology became irregular， reduced in size with condensed cytoplasmic， and apoptotic vesicles with irregular morphology were seen around the cells， among which the most obvious changes were seen in the combination group. Under fluorescence observation， the cells in the control group only displayed green fluorescence. In all drug-treated groups， cells with red fluorescence were observed， with the combination group having the highest percentage of cells with red fluorescence among the total cell population. The apoptosis rates for the control group， dihydroartemisinin group， carfilzomib group， and combination group were （9.06±2.95）%， （29.50±1.34）%， （20.77±3.00）%， and （58.23±5.13）%， respectively， and there was a statistically significant difference （F=115.80， P<0.001）. There were statistically significant differences in the dihydroartemisinin group， carfilzomib group， and combination group compared with control group （P<0.001； P=0.012； P<0.001）. There were statistically significant differences in the dihydroartemisinin group and carfilzomib group compared with combined group （both P<0.001）. There were statistically significant differences in the relative expression levels of P53， Cleaved-Caspase-3， Bcl-2， and Bax proteins among the control group， dihydroartemisinin group， carfilzomib group， and combination group （F=21.76， P<0.001； F=42.87， P<0.001； F=44.27， P<0.001； F=163.50， P<0.001）. There were statistically significant differences in the dihydroartemisinin group， carfilzomib group， and combination group compared with control group （all P<0.05）. There were statistically significant differences in the dihydroartemisinin group and carfilzomib group compared with combined group （both P<0.05）. Conclusion The combination of dihydroartemisinin and carfilzomib can synergistically inhibit the activity and proliferation of multiple myeloma ARD cells， and promote apoptosis， and the underlying mechanism may be associated with the mitochondrial apoptosis pathway. Figures and Tables | References | Related Articles | Metrics

Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin 2024, 51 (3):  137-142.  doi: 10.3760/cma.j.cn371439-20231109-00022 Abstract ( 76 )   HTML ( 18 )   PDF (821KB) ( 51 )   Save Objective To compare the clinical efficacy of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer （NSCLC）， and to explore its impact on tumor marker levels and immune function index， as well as to perform safety analysis. Methods A total of 87 patients with advanced NSCLC who were treated in Hai'an People's Hospital of Jiangsu Province from May 2019 to May 2021 were selected as the research objects. According to the treatment scheme， the patients were divided into camrelizumab group （n=41） and sintilimab group （n=46）. The clinical efficacy， prognosis， tumor marker levels， immune function index and immune related adverse reactions of the two groups were compared. Results There were no statistically significant differences in objective response rate [48.78% （20/41） vs. 39.13% （18/46）， χ2=0.82， P=0.365] or disease control rate [78.05% （32/41） vs. 71.74% （33/46）， χ2=0.46， P=0.499] in both camrelizumab and sintilimab group. The median progression-free survival （PFS） in the camrelizumab group was 9.1 months， and the median overall survival （OS） was 15.4 months. The median PFS in the sintilimab group was 9.7 months， and the median OS was 15.7 months. There were no statistically significant differences in median PFS and median OS between the two groups （χ2=0.18， P=0.633； χ2=0.15， P=0.697）. Before treatment， there were no statistically significant differences in carcinoembryonic antigen （CEA） [（47.68±8.12） ng/ml vs. （49.03±8.70） ng/ml， t=0.75， P=0.458]， cytokeratin 19 fragment antigen 21-1 （CYFRA21-1） [（18.06±3.41） ng/ml vs. （17.25±3.78） ng/ml， t=1.05， P=0.299]， and carbohydrate antigen 125 （CA125） [（72.26±21.06） U/ml vs. （74.03±22.10） U/ml， t=0.38， P=0.704] levels between the camrelizumab group and sintilimab group. After treatment， there were no statistically significant differences in CEA [（28.11±7.68） ng/ml vs. （27.63±5.71） ng/ml， t=0.33， P=0.740]， CYFRA21-1 [（9.29±1.88） ng/ml vs. （9.06±1.80） ng/ml， t=0.15， P=0.814]， and CA125 [（61.39±21.22） U/ml vs. （60.51±11.03） U/ml， t=0.25， P=0.806] levels between the two groups， but CEA， CYFRA21-1， and CA125 levels decreased after treatment compared with those before treatment in both groups （all P<0.05）. Before treatment， there were no statistically significant differences in T cells CD4+ [（41.15±3.24）% vs. （41.17±2.90）%， t=0.03， P=0.976]， CD8+ [（68.82±3.94）% vs. （70.06±4.08）%， t=1.44， P=0.154]， and CD4+/CD8+ （1.88±0.33 vs. 1.76±0.25， t=1.92， P=0.058） between the two groups. After treatment， there were no statistically significant differences in T cells CD4+ [（47.08±3.22）% vs. （48.53±5.07）%， t=1.57， P=0.120]， CD8+ [（61.22±1.67）% vs. （61.45±1.66）%， t=0.64， P=0.522]， and CD4+/CD8+ （2.31±0.17 vs. 2.36±0.12， t=1.60， P=0.114） between the two groups， while T cells CD8+ was lower than that before treatment， and CD4+ as well as CD4+/CD8+ were higher than those before treatment in both groups （all P<0.05）. The overall incidence of adverse reactions in the sintilimab group [10.87% （5/46）] was lower than that in the camrelizumab group [31.71% （13/41）]， and with a statistically significance （χ2=5.74， P=0.016）. Conclusion The clinical efficacy of camrelizumab and sintilimab in NSCLC patients is basically the same， the impacts of which on tumor markers and immune function are comparable， but the safety of sintilimab is better than that of camrelizumab. Figures and Tables | References | Related Articles | Metrics

Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao 2024, 51 (3):  143-150.  doi: 10.3760/cma.j.cn371439-20231109-00023 Abstract ( 63 )   HTML ( 13 )   PDF (1767KB) ( 59 )   Save Objective To explore influencing factors affecting the prognosis of patients with advanced non-small cell lung cancer （NSCLC） receiving immunotherapy based on hematologic indexes， thus to construct and evaluate a nomogram prediction model. Methods The clinical data of 80 patients with advanced NSCLC treated with programmed death-1 inhibitor monotherapy or combination regimen from January 2018 to June 2020 at the Affiliated Hospital of North China University of Science and Technology and Tangshan People's Hospital were retrospectively analyzed. Hematologic indexes at the baseline， the optimal remission and the progressive disease （PD） were collected separately， and independent influencing factors for patient prognosis were analyzed using Cox proportional hazards regression model. A nomogram prediction model was constructed based on the results of the multifactorial analysis， and the predictive performance of the model was evaluated by receiver operating characteristic （ROC） curve， concordance index （C-index） and calibration curves. Results As of the follow-up cut-off date， of the 80 patients， 63 had PD， with a median overall survival （OS） of 16.9 months. Univariate analysis showed that， age （HR=2.09， 95%CI： 1.17-3.74， P=0.013）， number of treatment lines （HR=2.23， 95%CI： 1.21-4.12， P=0.010）， lymphocyte to monocyte ratio （LMR） at the baseline （HR=0.75， 95%CI： 0.57-0.97， P=0.028）， D-dimer （HR=1.00， 95%CI： 1.00-1.00， P=0.002） and lactate dehydrogenase （LDH） （HR=1.01， 95%CI： 1.00-1.01， P=0.006） at the optimal remission， haemoglobin （HR=0.97， 95%CI： 0.96-0.99， P<0.001）， D-dimer （HR=1.00， 95%CI： 1.00-1.00， P=0.002）， C-reactive protein （HR=1.01， 95%CI： 1.00-1.01， P=0.011）， albumin （ALB） （HR=0.91， 95%CI： 0.87-0.96， P=0.001）， neutrophil to lymphocyte ratio （NLR） （HR=1.16， 95%CI： 1.05-1.27， P=0.002） and LMR （HR=0.62， 95%CI： 0.42-0.90， P=0.012） at the PD were all influencing factors for the prognosis of advanced NSCLC patients receiving immunotherapy. Least absolute shrinkage and selection operator regression were used to screen the variables for P<0.10 in the univariate analysis， and nine possible influencing factors were obtained， which were age， fibrinogen and LDH at the optimal remission， haemoglobin， D-dimer， C-reactive protein， LDH， ALB and LMR at the PD. Multivariate analysis of the above variables showed that， age （HR=0.91， 95%CI： 0.86-0.97， P=0.004）， LDH （HR=1.01， 95%CI： 1.00-1.01， P=0.013） and ALB （HR=0.82， 95%CI： 0.67-0.99， P=0.041） at the PD were independent influencing factors for the prognosis of patients with advanced NSCLC who received immunotherapy. The area under curve of the nomogram predicting model based on the above indexes， 1- and 2-year OS rates of patients were 0.77 （95%CI： 0.65-0.89） and 0.75 （95%CI： 0.66-0.88）， respectively， and C-index was 0.71 （95%CI： 0.64-0.78）， the calibration curves showed good consistency between predicted and actual probability of occurrence. Patients in the low-risk group （n=40） had a median OS of 29.9 months （95%CI： 22.5 months-NA）， which was significantly better than that of the high-risk group （n=40） [13.4 months （95%CI： 11.4-23.5 months）， χ2=11.30， P<0.001]. Conclusion Age， LDH and ALB at the PD are independent influencing factors affecting the prognosis of patients with advanced NSCLC receiving immunotherapy， and the nomogram model constructed based on the above indexes has good differentiation and calibration for predicting 1- and 2-year OS rates in advanced NSCLC patients receiving immunotherapy. Figures and Tables | References | Related Articles | Metrics

A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma Qian Xiaotao, Shi Ziyi, Hu Ge 2024, 51 (3):  151-156.  doi: 10.3760/cma.j.cn371439-20230506-00024 Abstract ( 53 )   HTML ( 12 )   PDF (1049KB) ( 38 )   Save Objective To investigate the efficacy of immune checkpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma （ESCC） in the real world. Methods The clinical data of 65 patients with stage Ⅲ-ⅣA ESCC treated by radical radiotherapy and chemotherapy from January 1， 2018 to December 31， 2022 in Hefei Cancer Hospital， Chinese Academy of Sciences were retrospectively analyzed. According to whether to undergo immune checkpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy， the patients were divided into a control group （n=29） and an immune maintenance therapy group （n=36）. The objective response rate （ORR）， progression-free survival （PFS）， and overall survival （OS） between the two groups were compared. Kaplan-Meier method was used to draw the survival curve accompanied with log-rank test. Cox regression model was used to conduct both univariate and multivariate analyses. Results The ORR was 34.5% （10/29） in the control group and 61.1% （22/36） in the immune maintenance therapy group， with a statistically significant difference （χ2=4.56， P=0.032）. The median PFS of control group and immune maintenance therapy group were 7.2 and 17.9 months， respectively， with a statistically significant difference （χ2=7.86， P=0.005）. The median OS was 14.1 and 27.8 months， respectively， with a statistically significant difference （χ2=5.40， P=0.020）. Univariate analysis showed that， objective response （HR=0.09， 95%CI： 0.03-0.28， P<0.001） and immune maintenance therapy （HR=0.38， 95%CI： 0.17-0.88， P=0.024） were the influential factors of OS in ESCC patients treaded by radical chemoradiotherapy in stage Ⅲ-ⅣA. Multivariate analysis showed that， objective response （HR=0.09， 95%CI： 0.03-0.29， P<0.001） and immune maintenance therapy （HR=0.40， 95%CI： 0.17-0.92， P=0.032） were the independent influencing factors for OS in ESCC patients treaded by radical chemoracial therapy in stage Ⅲ-ⅣA. The incidence of adverse reactions was 22.22% （8/36） in the immune maintenance therapy group and 10.34% （3/29） in the control group， with no statistically significant difference （χ2=1.61， P=0.204）. All the adverse reactions were grade 1-2， and the symptoms were relieved after symptomatic treatment. Conclusion Maintenance therapy with immune checkpoint inhibitors after radical chemoradiotherapy of stage Ⅲ-ⅣA ESCC can significantly improve the prognosis of patients with good safety. Figures and Tables | References | Related Articles | Metrics

Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer Xie Shuping, Sun Yahong, Wang Chao 2024, 51 (3):  157-165.  doi: 10.3760/cma.j.cn371439-20231016-00025 Abstract ( 68 )   HTML ( 10 )   PDF (1963KB) ( 33 )   Save Objective To explore the predictive value of early serum tumor markers （STM）， neutrophil to lymphocyte ratio （NLR）， platelet to lymphocyte ratio （PLR） combination score on the efficacy of gastric cancer immunotherapy. Methods A total of 76 patients with gastric cancer who received immunotherapy at Second Affiliated Hospital of Shandong First Medical University from January 1， 2020 to June 30， 2022 were selected. Patients' leading STM， NLR， PLR were collected. Optimal cut-off value of NLR and PLR were determined by the receiver operating characteristic （ROC） curve. The clinical efficacy and prognosis of different leading STM， NLR， PLR and combined scores in gastric cancer patients received immunotherapy were analyzed. ROC curve was used to evaluate the predictive efficiency of each index and the combined score. Cox regression model was used to analyze the factors affecting patients' survival. Results The best truncation value for NLR was 2.75， and the best truncation value for PLR was 175.9. All patients completed at least 2 cycles of immunotherapy， the objective response rate （ORR） was 23.7% （18/76）， and the disease control rate （DCR） was 88.2% （67/76）. There were no significant differences in ORR [（20.9% （9/43） vs. 27.3% （9/33）]， DCR [83.7% （36/43） vs. 93.9% （31/33）] between the high NLR group （n=43） and low NLR group （n=33） （χ2=0.42， P=0.519； χ2=1.02， P=0.313）. There were no significant differences in ORR [27.3% （12/44） vs. 18.8% （6/32）]， DCR [81.8% （36/44） vs. 96.9% （31/32）] between the high PLR group （n=44） and low PLR group （n=32） （χ2=0.75， P=0.388； χ2=2.71， P=0.555）. The ORR for the high combined score group （n=39） and low combined score group （n=37） was 17.9% （7/39） and 29.7% （11/37）， respectively， with no statistically significant difference （χ2=1.46， P=0.230）； the DCR was 79.5% （31/39） and 97.3% （36/37）， respectively， with a statistically significant difference （χ2=4.19， P=0.041）. The median progression free survival （PFS） and overall survival （OS） of 76 patients were 8.0 and 12.0 months. The median PFS in the high NLR group and low NLR group was 7.0 and 10.0 months， respectively， with a statistically significant difference （χ2=7.95， P=0.005）； the median OS was 12.0 and 14.0 months， respectively， with no statistically significant difference （χ2=1.04， P=0.307）. The median PFS in the high PLR group and low PLR group was 8.0 and 10.0 months， respectively， with a statistically significant difference （χ2=3.90， P=0.048）； the median OS was 13.0 and 13.0 months， respectively， with no significant difference （χ2=0.02， P=0.896）. The median PFS in the high combined score group and low combined score group was 7.0 and 10.0 months， respectively， with a statistically significant difference （χ2=13.52， P<0.001）； the median OS was 12.0 and 14.0 months， respectively， with a statistically significant difference （χ2=5.02， P=0.025）. ROC curve analysis showed that the area under curve （AUC） of leading STM， NLR， PLR and combined score to predict the efficacy of gastric cancer immunotherapy was 0.662， 0.697， 0.601 and 0.773. Univariate analysis showed that， surgery （HR=0.59， 95%CI： 0.36-0.95， P=0.031）， leading STM （HR=0.57， 95%CI： 0.34-0.93， P=0.026）， NLR （HR=0.54， 95%CI： 0.34-0.87， P=0.011）， combined score （HR=0.42， 95%CI： 0.26-0.68， P<0.001） were all influencing factors for PFS in gastric cancer patients received immunotherapy； tumor stage （HR=0.30， 95%CI： 0.12-0.75， P=0.011）， leading STM （HR=0.28， 95%CI： 0.15-0.50， P<0.001）， combined score （HR=0.55， 95%CI： 0.31-0.96， P=0.036） were all influencing factors for OS in gastric cancer patients received immunotherapy. Multivariate analysis showed that， leading STM （HR=0.56， 95%CI： 0.33-0.98， P=0.041） was an independent influencing factor for PFS in gastric cancer patients received immunotherapy； tumor stage （HR=0.29， 95%CI： 0.11-0.76， P=0.012）， leading STM （HR=0.32， 95%CI： 0.17-0.58， P<0.001）， combined score （HR=0.46， 95%CI： 0.25-0.82， P=0.009） were all independent influencing factors for OS in gastric cancer patients received immunotherapy. Conclusion The combined score of leading STM， NLR and PLR is an independent factor influencing OS in patients receiving immunotherapy for gastric cancer， and can predict the efficacy of immunotherapy for gastric cancer. Figures and Tables | References | Related Articles | Metrics

Reviews

Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinoma in situ of the breast Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng 2024, 51 (3):  166-169.  doi: 10.3760/cma.j.cn371439-20231130-00026 Abstract ( 89 )   HTML ( 9 )   PDF (657KB) ( 53 )   Save Ductal carcinoma in situ of the breast （DCIS） most commonly manifests as asymptomatic calcifications at mammography. The most common manifestation of MRI is nonmass enhancement. The ultrasound mainly presents as a hypoechoic irregular hypervascular mass without posterior features. Core-needle biopsy is a commonly used method for preoperative diagnosis of DCIS. Due to differences in needle type and sample size， there is a certain degree of pathological upgrading of the lesion. In recent years， there has been controversy over the diagnosis and treatment of DCIS. With the development of breast disease diagnostic technology， advances in digital breast tomography， artificial intelligence， and radiomics are expected to help DCIS management and address issues such as overdiagnosis. References | Related Articles | Metrics

Progress of radiotherapy in oligometastatic non-small cell lung cancer Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing 2024, 51 (3):  170-174.  doi: 10.3760/cma.j.cn371439-20231130-00027 Abstract ( 75 )   HTML ( 5 )   PDF (696KB) ( 51 )   Save The effective local management of oligometastatic non-small cell lung cancer （NSCLC） has the potential to prolong patients' survival. The role of radiotherapy as a local treatment modality in patients with oligometastatic NSCLC， whether as first-line therapy or consolidation therapy， remains uncertain. Several studies have demonstrated that stereotactic ablative radiotherapy can offer clinical benefits for patients with oligometastatic NSCLC without increasing adverse reactions. Furthermore， the exploration of the potential synergistic effects of combining radiotherapy and immunotherapy on extending progression-free survival and overall survival in patients with oligometastatic NSCLC is also a topic worthy of attention. References | Related Articles | Metrics

Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan 2024, 51 (3):  175-180.  doi: 10.3760/cma.j.cn371439-20231109-00028 Abstract ( 83 )   HTML ( 5 )   PDF (718KB) ( 36 )   Save The high intra- and inter-tumor heterogeneity of gastric cancer leads to a great difference in the immunotherapy efficacy and the prognosis among patients. Several biomarkers， including programmed death-ligand 1， human epidermal growth factor receptor 2， the features of tumor microenvironment， the peripheral blood inflammatory markers and Claudin18.2 have predictive value in the immunotherapy efficacy and the prognosis of gastric cancer patients， which might help the clinicians find the potential patients who will benefit from immunotherapy， and achieve the goal of precision medicine. References | Related Articles | Metrics

Advances on KPNA2 in liver cancer Peng Qin, Cai Yuting, Wang Wei 2024, 51 (3):  181-185.  doi: 10.3760/cma.j.cn371439-20231026-00029 Abstract ( 85 )   HTML ( 19 )   PDF (670KB) ( 45 )   Save Karyopherin α2 （KPNA2）， a key protein molecule that regulates the exchange of substances between the nucleus and the cytoplasm， plays an important role in the nucleocytoplasmic transport pathway. In recent years， an increasing number of studies have shown that KPNA2 is involved in a variety of cellular life activities and plays a significant part in viral infection， cell proliferation， immune response and tumor metastasis. Further study of the mechanism of KPNA2 in promoting the hepatocarcinogenesis and exploring its role in the development of liver cancer may provide new ideas for the diagnosis， treatment， and prognosis of liver cancer. References | Related Articles | Metrics

Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer Gong Yan, Chen Honglei 2024, 51 (3):  186-190.  doi: 10.3760/cma.j.cn371439-20231109-00030 Abstract ( 65 )   HTML ( 8 )   PDF (703KB) ( 28 )   Save Cisplatin resistance is an important factor in the poor treatment effect of ovarian cancer patients. MicroRNA （miRNA） can regulate cellular structural molecules， DNA repair， cell cycle， apoptosis and Wnt/β-catenin signaling pathway， autophagy， methylation and cancer stem cell， which are involved in the regulation of cisplatin resistance in ovarian cancer. Further understanding the mechanism of miRNA regulation of cisplatin resistance in ovarian cancer will help find new treatment options to optimize existing treatment plans and improve efficacy. References | Related Articles | Metrics